A detailed history of Bank Of America Corp transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 459,765 shares of CPRX stock, worth $9.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
459,765
Previous 408,206 12.63%
Holding current value
$9.11 Million
Previous $6.51 Million 9.45%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$14.68 - $16.92 $756,886 - $872,378
51,559 Added 12.63%
459,765 $7.12 Million
Q1 2024

May 15, 2024

SELL
$13.18 - $17.11 $4.49 Million - $5.83 Million
-340,802 Reduced 45.5%
408,206 $6.51 Million
Q4 2023

Feb 14, 2024

BUY
$11.78 - $17.29 $1.02 Million - $1.5 Million
87,004 Added 13.14%
749,008 $12.6 Million
Q2 2023

Aug 14, 2023

SELL
$11.5 - $18.08 $3.72 Million - $5.86 Million
-323,876 Reduced 32.85%
662,004 $8.9 Million
Q1 2023

May 12, 2023

BUY
$14.34 - $21.05 $995,683 - $1.46 Million
69,434 Added 7.58%
985,880 $16.3 Million
Q4 2022

Feb 10, 2023

BUY
$12.25 - $19.5 $5.39 Million - $8.58 Million
440,187 Added 92.43%
916,446 $17 Million
Q3 2022

Nov 14, 2022

BUY
$7.06 - $15.52 $2.51 Million - $5.53 Million
356,077 Added 296.28%
476,259 $6.11 Million
Q2 2022

Aug 12, 2022

SELL
$6.23 - $8.57 $829,487 - $1.14 Million
-133,144 Reduced 52.56%
120,182 $842,000
Q1 2022

May 16, 2022

SELL
$5.31 - $8.31 $491,392 - $769,015
-92,541 Reduced 26.76%
253,326 $2.1 Million
Q4 2021

Feb 08, 2022

BUY
$5.21 - $7.45 $1.14 Million - $1.63 Million
219,197 Added 173.05%
345,867 $2.34 Million
Q3 2021

Nov 15, 2021

SELL
$4.85 - $6.04 $276,847 - $344,775
-57,082 Reduced 31.06%
126,670 $672,000
Q2 2021

Sep 13, 2021

BUY
$4.29 - $6.05 $788,296 - $1.11 Million
183,752 New
183,752 $1.06 Million

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.04B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.